Hybridoma cell line G250 and its use for producing monoclonal antibodies
This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.
1. A method for treating a renal cell carcinoma patient after tumor surgery, said method comprising:
administering a monospecific and non-radiolabeled G250 monoclonal antibody to said patient after tumor surgery, wherein said G250 antibody increases the survival of said patient compared to untreated patients, and wherein said G250 antibody comprises:
the heavy chain CDR sequences of SEQ ID NO:2; and
the light chain CDR sequences of SEQ ID NO:4.
2. The method according to claim 1 , wherein said G250 antibody is administered in an amount sufficient to treat metastases after tumor surgery.
3. The method according to claim 2 , wherein said G250 antibody is administered once per week.
4. The method according to claim 1 , wherein said G250 antibody is directly or indirectly obtained from hybridoma cell DSM ACC 2526.
5. The method according to claim 1 , wherein said G250 antibody is a chimeric antibody, a humanized antibody, a single chain antibody, or a F(ab′)2, a Fab′, or a Fab antibody fragment.
6. The method according to claim 5 , wherein the antibody is a chimeric G250 antibody.
7. The method according to claim 6 , wherein said chimeric G250 antibody is coupled to a cytokine.
8. The method according to claim 7 , wherein said cytokine is selected from the group consisting of IL-2, TNF and GM-CSF.
9. The method according to claim 4 , wherein the G250 antibody is indirectly obtained from hybridoma cell DSM ACC 2526 by transfer of genetic material encoding antibody G250 or the antigen-binding site thereof into a receptor cell which then produces the antibody G250.
10. A method for treating a renal cell carcinoma patient after tumor surgery, said method comprising:
administering a monospecific and non-radiolabeled G250 monoclonal antibody to said patient after tumor surgery, wherein said G250 antibody comprises the heavy and light chain CDR sequences of SEQ ID NOs: 2 and 4 respectively and wherein said method increases the survival of said patient compared to patients treated with high dose interleukin 2.
11. A method for treating a renal cell carcinoma patient after tumor surgery, said method comprising:
administering a monospecific and non-radiolabeled G250 monoclonal antibody comprising the heavy and light chain CDR sequences of SEQ ID NOs: 2 and 4 respectively to said patient after tumor surgery, wherein said G250 antibody increases the survival of said patient to at least 6 months after start of treatment.
12. The method of claim 1 , wherein the administering of said G250 antibody to the patient after tumor surgery generates an immune response against the renal cell carcinoma.
13. The method of claim 10 , wherein said G250 antibody is directly or indirectly obtained from hybridoma cell DSM ACC 2526.
14. The method of claim 10 , wherein said G250 antibody is a chimeric antibody, a humanized antibody, a single chain antibody, or a F(ab′)2, a Fab′, or a Fab antibody fragment.
15. The method of claim 10 , wherein the administering of said G250 antibody to the patient after tumor surgery generates an immune response against the renal cell carcinoma.
16. The method of claim 11 , wherein said G250 antibody is directly or indirectly obtained from hybridoma cell DSM ACC 2526.
17. The method of claim 11 , wherein said G250 antibody is a chimeric antibody, a humanized antibody, a single chain antibody, or a F(ab′)2, a Fab′, or a Fab antibody fragment.
18. The method of claim 11 , wherein the administering of said G250 antibody to the patient after tumor surgery generates an immune response against the renal cell carcinoma.
19. The method of claim 6 , wherein the chimeric G250 antibody comprises a human Fc region.
20. The method of claim 14 , wherein the G250 antibody is a chimeric antibody comprising a human Fc region.
21. The method of claim 17 , wherein the G250 antibody is a chimeric antibody comprising a human Fc region.
22. The method of claim 1 , wherein the renal cell carcinoma is metastatic renal cell carcinoma.
23. The method of claim 10 , wherein the renal cell carcinoma is metastatic renal cell carcinoma.
24. The method of claim 11 , wherein the renal cell carcinoma is metastatic renal cell carcinoma.